Homology Medicines Inc

Homology Medicines Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.947
  • Today's Change-0.063 / -6.24%
  • Shares traded214.86k
  • 1 Year change-68.64%
  • Beta-0.0482
Data delayed at least 15 minutes, as of Mar 30 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.

  • Revenue in USD (TTM)3.21m
  • Net income in USD-5.01m
  • Incorporated2015
  • Employees92.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Unrivaled Brands Inc61.91m-210.93m11.29m170.00------0.1823-0.3663-0.35080.109-0.07520.39544.5713.75185,350.30-134.71-27.36-314.40-35.7931.5733.96-340.72-132.540.0607-17.62----673.7913.48-485.45------
Trees Corp12.89m-7.57m14.53m77.00--2.00--1.13-0.0838-0.08450.13810.08670.50957.4396.11167,342.30-29.63-126.64-34.91-580.8139.8024.38-58.17-246.711.37-0.3710.623---16.7514.730.2624--51.59--
Yoshitsu Co Ltd (ADR)228.44m3.27m34.80m54.009.590.787.720.15230.10010.10017.591.231.936.605.17--2.77--6.53--17.10--1.43--
Homology Medicines Inc3.21m-5.01m54.62m92.00--0.305930.6917.03-0.0992-0.09920.05583.100.0146----34,869.570.2195-31.220.2413-33.71----15.06-818.17----0.00---90.56--94.77---8.08--
China Jo-Jo Drugstores Holdings Inc158.63m-3.52m89.81m911.00--1.01--0.5662-0.9731-0.973139.594.361.456.969.90174,127.50-3.22-8.29-9.51-23.5523.9822.07-2.22-5.890.7688--0.5619--23.4815.0760.69---5.73--
Rite Aid Corp24.06bn-897.69m122.09m53.00k------0.0051-16.50-16.50441.76-7.142.729.8014.50454,045.10-10.14-3.96-15.04-5.7719.9321.12-3.73-1.580.60090.34731.14--2.181.39-438.10---5.56--
Marimed Inc134.01m13.47m135.22m592.,368.309.89-16.3912.11-22.2247.7351.6910.16-19.660.931331.090.2425--10.3385.7086.42---9.49--
Tabula Rasa HealthCare Inc299.52m-77.33m139.73m1.03k------0.4665-3.18-6.0912.34-2.100.67838.737.37291,641.70-17.50-12.88-21.86-15.3122.3428.68-25.82-20.931.60-5.981.22--15.2517.54-48.04--34.14--
Data as of Mar 30 2023. Currency figures normalised to Homology Medicines Inc's reporting currency: US Dollar USD

Institutional shareholders

22.56%Per cent of shares held by top holders
HolderShares% Held
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 20225.65m9.83%
The Vanguard Group, Inc.as of 31 Dec 20222.03m3.53%
Bellevue Asset Management AGas of 31 Dec 20221.62m2.82%
Citadel Advisors LLCas of 31 Dec 20221.01m1.76%
BlackRock Fund Advisorsas of 31 Dec 2022917.41k1.60%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2022412.37k0.72%
Geode Capital Management LLCas of 31 Dec 2022386.01k0.67%
Renaissance Technologies LLCas of 31 Dec 2022333.15k0.58%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Dec 2022323.03k0.56%
Oasis Management (Hong Kong) LLCas of 31 Dec 2022280.00k0.49%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.